Priya Rao

6PUBLICATIONS
96CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 20, 2026
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.

|Nov 25, 2025
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.

Melinda Soeung, Xinmiao Yan, Ciro Zanca

|Jul 02, 2025
Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.

Niki M Zacharias, Manuel Ozambela, Menuka Karki

|Jan 21, 2025
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation.

Sandra L Grimm, Menuka Karki, Kyle A Blum

|Aug 29, 2024
A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer.

Matthew T Campbell, Amishi Y Shah, Pavlos Msaouel

|Apr 20, 2022
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.

Pavlos Msaouel, Sangeeta Goswami, Peter F Thall

Pageof 1

Frequent Collaborators

6 joint publications

Pavlos Msaouel

6 joint publications

Nizar M Tannir

4 joint publications

Rahul A Sheth

4 joint publications

Giannicola Genovese